Citizens Capital Markets Reiterates Market Outperform on AN2 Therapeutics, Maintains $5 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Citizens Capital Markets analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintains $5 price target.
Citizens Capital Markets analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintains $5 price target.